Kaletra (Lopinavir, Ritonavir)

Lopinavir blocks the HIV‑1 protease enzyme, preventing the virus from processing its polyprotein precursors into functional components needed for new virus particles. Ritonavir, given at a low dose, inhibits the CYP3A4 enzyme that metabolises lopinavir, thereby boosting lopinavir plasma levels and prolonging its antiviral effect.

The dosage of Kaletra is individualized and must be determined by the prescribing clinician based on the patient’s age, weight, treatment history, and laboratory results. Healthcare providers follow established guidelines and adjust the regimen as needed to achieve optimal viral suppression.

Kaletra is classified as pregnancy category B3, indicating that animal studies have shown some risk but there are no adequate human studies. It should be used in pregnancy only when the potential benefits justify the potential risks. Limited data are available for breastfeeding; the decision should be made by the prescriber in consultation with the mother.

To order Kaletra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Kaletra offers a protease‑inhibitor based regimen that is often used when patients have resistance to non‑nucleoside reverse transcriptase inhibitors or integrase inhibitors. Compared with some newer agents, it may have a higher pill burden and more metabolic side effects, but its well‑established efficacy and the boosting effect of ritonavir make it a reliable component of combination therapy.

Kaletra tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Kaletra is taken orally, usually with food to improve absorption. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not skip doses or alter the timing without medical advice.

Serious adverse reactions include hepatotoxicity, pancreatitis, severe allergic responses such as anaphylaxis, and cardiac effects like QT‑interval prolongation. Patients should be monitored regularly for liver enzyme elevations, abdominal pain, skin reactions, and any signs of cardiac arrhythmia, and they should seek immediate medical attention if these symptoms occur.

Kaletra is contraindicated in patients with known hypersensitivity to lopinavir, ritonavir, or any of the tablet excipients. It should also be avoided in individuals taking strong CYP3A inducers that would markedly reduce drug exposure, and in patients with pre‑existing severe liver disease unless closely supervised by a specialist.